Over the past two years, Merck (NYSE: MRK) has faced several challenges, resulting in a decline in the company's share price.

While the FDA is streamlining regulation of copycat versions of the expensive drugs that millions take for arthritis, cancer, and other diseases, the U.S. patent office is making it harder for the ...

Regulators approved the injection, which significantly cuts administration time versus the intravenous formulation, based on a Phase III comparison of the two.

This is the first and only subcutaneous immune checkpoint inhibitor in Europe that a health care provider can administer in ...

Merck & Co. has won European Commission approval of a formulation of its blockbuster cancer drug Keytruda that can be injected under the skin. The Rahway, N.J., drugmaker on Wednesday said the green ...

Merck (MRK) announced that the European Commission has approved a new subcutaneous, or under the skin, route of administration and a new ...

We are honored to introduce KEYTRUDA SC, the first and only subcutaneous immune checkpoint inhibitor in Europe that can be administered in one minute every three weeks or in two minutes every six ...

Merck on Tuesday said its drug, Winrevair, met the primary endpoint in a Phase 2 study in adults with post- and precapillary pulmonary hypertension due to heart failure. The Rahway, N.J., ...

Merck will acquire Cidara Therapeutics in a nearly $9.2 billion deal, gaining access to an experimental flu drug in its ...

Merck & Co., Inc. acquires Cidara Therapeutics, Inc. for $9.2bn, boosting its pipeline with CD388's strong flu data. Click ...

Merck will pay $221.50 a share in cash for Cidara in a tender offer, more the twice Thursday’s closing price, for a total ...